PDCI Market Access’s International Trends Series provides the results of an online survey conducted by PDCI between March 19, 2015 and March 25, 2015. Participants were payer and industry stakeholders in both Europe and Canada. The current issue presents the perspectives of both private and public payers, and industry representatives on reassessments of currently covered products to change or downgrade their coverage status. Please click here for a complimentary copy of the third issue, “Downgrading of Benefits.”
Over the coming weeks, we will be releasing a series of papers focusing on the following issues about which participants were asked to share their insights:
- Delisting of Oncology Treatments
- Off-Label Prescribing Provisions
- Downgrading of Benefits
- Uptake of Biosimilars
- Private Payer Exclusivity Agreements
If you have any questions regarding the paper, please contact Courtney Abunassar, PDCI’s Manager of Market Access and Policy Research.